China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has struck a partnership with Shanghai Tenth People’s Hospital to establish a precision genomics testing center. This collaboration aims to enhance the capabilities of both institutions in the field of genomics and molecular diagnostics.
Precision Genomics Testing Center
Specifically, the two parties will set up a genomics and microbiology detection and analysis service platform. This platform will carry out laboratory-developed test (LDT) programs, academic research, technical research and transformation, product clinical research and application, talent training, and more. The establishment of this center is expected to significantly advance the field of precision medicine in the region.
Background and Policy Support
The Shanghai government previously released a document related to LDT infrastructure, encouraging eligible hospitals to develop their own in vitro diagnostic reagents. This policy provides a supportive environment for the partnership between Sansure Biotech and Shanghai Tenth People’s Hospital, facilitating the development and implementation of innovative diagnostic solutions.
Strategic Implications
This partnership between Sansure Biotech and Shanghai Tenth People’s Hospital represents a strategic move to combine the strengths of a leading biotech company with a renowned medical institution. By establishing a precision genomics testing center, the two parties aim to improve diagnostic accuracy, accelerate research and development, and enhance the overall quality of healthcare services. This collaboration is expected to contribute to the advancement of precision medicine and benefit patients through more personalized and effective diagnostic and treatment options.-Fineline Info & Tech
